Topics

Bayer and Foundation Medicine Collaborate to Develop Next-Generation Sequencing-Based Companion Diagnostics in Oncology

15:09 EDT 29 May 2019 | Speciality Pharma Journal

CAMBRIDGE, Mass. and BERLIN, May 29, 2019 /PRNewswire/ — Bayer AG and Foundation Medicine, Inc. today announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.  This agreement allows for collaboration across multiple oncology drug candidates and approved therapies developed by Bayer and covers Foundation Medicine’s full portfolio of tests, including FoundationOne®CDx. …

Original Article: Bayer and Foundation Medicine Collaborate to Develop Next-Generation Sequencing-Based Companion Diagnostics in Oncology

NEXT ARTICLE

More From BioPortfolio on "Bayer and Foundation Medicine Collaborate to Develop Next-Generation Sequencing-Based Companion Diagnostics in Oncology"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...